Prosecution Insights
Last updated: August 15, 2026

Corcept Therapeutics Incorporated

8 pending office actions • 5 art units • 8 examiners • 0 of 8 (0%) have an AI response strategy ready • 9 patents granted in the last 365 days

Portfolio Summary

8
Total Pending OAs
8
Non-Final OAs
0
Final Rejections
0
Advisory / Quayle

Response Deadline Pressure

Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.

0
Overdue
0
Due this week
0
Due this month
1
Due in next 60 days
0
Due later

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

1
Hard (12%)
3
Medium (38%)
4
Easy (50%)
0
Unknown (0%)

Rejection Statute Mix

BucketCases
§103 only1 (12%)
Double-patenting only4 (50%)
Double-patenting + other2 (25%)
Multi-statute (no §101)1 (12%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

5
Life Sciences
62% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
0
Mechanical / Eng
0% of docket
3
Business / Other
38% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

80 h
Manual time on pending OAs
16 h
Time saved (low, 20%)
28 h
Time saved (mid, 35%)
0.7 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
SEAMAN, D MARGARET M 1 76.6% +8.0%
WHITE, DAWANNA SHAR-DAY 1 62.3% +20.3%
ROZOF, TIMOTHY R 1 72.7% +23.9%
HEASLEY, MEGHAN CHRISTINE 1 76.6% +34.8%
KUCHARCZK, JED A 1 79.6% +16.9%
YOO, SUN JAE 1 71.0% +0.3%
DENT, ALANA HARRIS 1 44.3% +32.1%
LEE, CHIHYI NMN 1 32.9% +58.5%

Hard Cases (1)

Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.

App #TitleExaminerDue in
18342239 METHODS OF PREPARING HETEROARYL-KETONE FUSED AZADECALIN GLUCOCORTICOID RECEPTOR MODULATORS LEE, CHIHYI NMN 55d

Interview Candidates (6)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 6 ordered by deadline are shown.

App #TitleExaminerDue in
18342239 METHODS OF PREPARING HETEROARYL-KETONE FUSED AZADECALIN GLUCOCORTICOID RECEPTOR MODULATORS LEE, CHIHYI NMN 55d
18798160 PIPERAZINE INDAZOLE GLUCOCORTICOID RECEPTOR ANTAGONISTS WHITE, DAWANNA SHAR-DAY
18777823 Therapeutic Uses of Relacorilant, a Heteroaryl-ketone Fused Azadecalin Glucocorticoid Receptor Modulator ROZOF, TIMOTHY R
18764781 BICYCLIC INDAZOLE GLUCOCORTICOID RECEPTOR ANTAGONISTS HEASLEY, MEGHAN CHRISTINE
18686112 METHODS AND COMPOSITIONS FOR TREATING HUNTINGTON'S DISEASE AND ITS SYMPTOMS KUCHARCZK, JED A
18460226 METHODS OF ASSESSING SELECTIVE GLUCOCORTICOID RECEPTOR MODULATION AND OF IDENTIFYING AND TREATING PATIENTS LIKELY TO BENEFIT FROM GLUCOCORTICOID RECEPTOR MODULATION DENT, ALANA HARRIS

Top Art Units

Art UnitApps
1626 1
1623 1
1621 1
1643 1
1628 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
18908611 POLYMORPHS OF PYRIMIDINE CYCLOHEXYL GLUCOCORTICOID RECEPTOR MODULATORS SEAMAN, D MARGARET M DP Non-Final OA Pending Oct 07, 2024
18798160 PIPERAZINE INDAZOLE GLUCOCORTICOID RECEPTOR ANTAGONISTS WHITE, DAWANNA SHAR-DAY DP Non-Final OA Pending Aug 08, 2024
18777823 Therapeutic Uses of Relacorilant, a Heteroaryl-ketone Fused Azadecalin Glucocorticoid Receptor Modulator ROZOF, TIMOTHY R DP Non-Final OA Pending Jul 19, 2024
18764781 BICYCLIC INDAZOLE GLUCOCORTICOID RECEPTOR ANTAGONISTS HEASLEY, MEGHAN CHRISTINE 1626 DP Non-Final OA Pending Jul 05, 2024
18686112 METHODS AND COMPOSITIONS FOR TREATING HUNTINGTON'S DISEASE AND ITS SYMPTOMS KUCHARCZK, JED A 1623 §103§112DP Non-Final OA Pending Feb 23, 2024
18412258 METHODS OF TREATING ANTIPSYCHOTIC-INDUCED WEIGHT GAIN WITH MIRICORILANT YOO, SUN JAE 1621 §102DP Non-Final OA Pending Jan 12, 2024
18460226 METHODS OF ASSESSING SELECTIVE GLUCOCORTICOID RECEPTOR MODULATION AND OF IDENTIFYING AND TREATING PATIENTS LIKELY TO BENEFIT FROM GLUCOCORTICOID RECEPTOR MODULATION DENT, ALANA HARRIS 1643 §103 Non-Final OA Pending Sep 01, 2023
18342239 METHODS OF PREPARING HETEROARYL-KETONE FUSED AZADECALIN GLUCOCORTICOID RECEPTOR MODULATORS LEE, CHIHYI NMN 1628 §102§103§112Other Non-Final OA 55d Pending Jun 27, 2023

Managing Corcept Therapeutics Incorporated's Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month